Ocular Therapeutix will present SOL-1 trial results for AXPAXLI™ in a webcast on February 17, 2026.
Quiver AI Summary
Ocular Therapeutix, Inc. has announced a webcast scheduled for February 17, 2026, at 8:00 AM ET to discuss the topline results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for treating wet age-related macular degeneration (wet AMD). Detailed data from this trial will be presented later at the 49th Macula Society Annual Meeting, taking place from February 25 to 28, 2026. The webcast can be accessed live and will be available for replay for at least 30 days on the company's website. Ocular Therapeutix focuses on advancing therapies for retinal diseases and is currently involved in clinical trials for a range of products, including AXPAXLI and DEXTENZA®, an FDA-approved treatment for ocular inflammation and pain.
Potential Positives
- Announcement of a webcast to present topline results of the SOL-1 Phase 3 clinical trial for AXPAXLI™ demonstrates Ocular's commitment to transparency and communication with stakeholders.
- Presentation of detailed data at a prestigious event like the 49th Macula Society Annual Meeting highlights the significance of the findings and the company's involvement in the retinal disease community.
- AXPAXLI™ is currently in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, indicating strong progression in Ocular's pipeline for critical treatment areas.
- The webcast and subsequent data availability may attract investor interest and bolster confidence in Ocular's research and development efforts.
Potential Negatives
- The press release does not provide specific results or insights regarding the topline data of the SOL-1 Phase 3 clinical trial, which may lead to uncertainty and speculation about the trial's success or failure.
- The reliance on future presentations at an upcoming conference for detailed data could create skepticism among investors who prefer immediate and comprehensive disclosure of trial outcomes.
- The absence of concrete information about the impact of AXPAXLI™ on wet AMD could diminish investor confidence in the viability and market potential of the investigational product.
FAQ
When is the Ocular webcast scheduled?
The Ocular webcast is scheduled for Tuesday, February 17, 2026, at 8:00 AM ET.
What will be presented at the 49th Macula Society Annual Meeting?
Detailed results of the SOL-1 Phase 3 clinical trial for AXPAXLI™ will be presented at the meeting.
How can I register for the Ocular webcast?
You can register for the webcast by clicking the registration link provided in the announcement.
What is AXPAXLI™ used to treat?
AXPAXLI™ is being developed for the treatment of wet age-related macular degeneration (wet AMD).
Where can I find a replay of the webcast?
The replay of the webcast will be available on the Ocular Therapeutix Investor Relations page for at least 30 days.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- NAMRATA SAROJ (Chief Business Officer) sold 25,865 shares for an estimated $277,790
- PRAVIN DUGEL (See Remarks) sold 21,494 shares for an estimated $258,787
- JEFFREY S. HEIER (Chief Scientific Officer) has made 0 purchases and 2 sales selling 13,565 shares for an estimated $152,820.
- PETER KAISER (Chief Development Officer) has made 0 purchases and 2 sales selling 12,664 shares for an estimated $142,725.
- TODD ANDERMAN (Chief Legal Officer) sold 11,132 shares for an estimated $137,368
- DONALD NOTMAN (Chief Operating Officer) has made 0 purchases and 3 sales selling 12,556 shares for an estimated $114,647.
- SANJAY NAYAK (Chief Strategy Officer) sold 1,885 shares for an estimated $22,695
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OCUL Hedge Fund Activity
We have seen 154 institutional investors add shares of $OCUL stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 12,177,463 shares (+62.1%) to their portfolio in Q3 2025, for an estimated $142,354,542
- BLACKROCK, INC. added 5,045,557 shares (+47.8%) to their portfolio in Q4 2025, for an estimated $61,253,061
- DEEP TRACK CAPITAL, LP removed 3,861,723 shares (-32.4%) from their portfolio in Q4 2025, for an estimated $46,881,317
- MILLENNIUM MANAGEMENT LLC added 3,736,560 shares (+3136.1%) to their portfolio in Q3 2025, for an estimated $43,680,386
- ALLIANCEBERNSTEIN L.P. added 3,261,619 shares (+2003.2%) to their portfolio in Q3 2025, for an estimated $38,128,326
- AVORO CAPITAL ADVISORS LLC added 2,850,000 shares (+38.5%) to their portfolio in Q3 2025, for an estimated $33,316,500
- POINT72 ASSET MANAGEMENT, L.P. added 2,697,107 shares (+141.6%) to their portfolio in Q3 2025, for an estimated $31,529,180
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OCUL Analyst Ratings
Wall Street analysts have issued reports on $OCUL in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 12/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/25/2025
- TD Cowen issued a "Buy" rating on 10/30/2025
- Baird issued a "Outperform" rating on 10/03/2025
- Piper Sandler issued a "Overweight" rating on 10/03/2025
- Needham issued a "Buy" rating on 10/01/2025
- JMP Securities issued a "Market Outperform" rating on 10/01/2025
To track analyst ratings and price targets for $OCUL, check out Quiver Quantitative's $OCUL forecast page.
$OCUL Price Targets
Multiple analysts have issued price targets for $OCUL recently. We have seen 7 analysts offer price targets for $OCUL in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Daniil Gataulin from Chardan Capital set a target price of $21.0 on 12/09/2025
- Yi Chen from HC Wainwright & Co. set a target price of $21.0 on 12/08/2025
- Serge Belanger from Needham set a target price of $20.0 on 12/08/2025
- Tara Bancroft from TD Cowen set a target price of $20.0 on 10/30/2025
- Colleen Kusy from Baird set a target price of $24.0 on 10/03/2025
- Biren Amin from Piper Sandler set a target price of $31.0 on 10/03/2025
- Jonathan Wolleben from JMP Securities set a target price of $29.0 on 10/01/2025
Full Release
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET
Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting
BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49 th Macula Society Annual Meeting between February 25 – 28, 2026.
Click here to register for the virtual webcast, which will begin at 8:00 AM ET.
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]
